Green Thumb Industries (GTBIF) Liabilities and Shareholders Equity (2019 - 2026)
Green Thumb Industries (GTBIF) posted Liabilities and Shareholders Equity of $2.8 billion for Q1 2026, up 1.49% on a QoQ basis from $2.8 billion in Q4 2025, and up 10.22% year-over-year from $2.6 billion in Q1 2025.
Green Thumb Industries (GTBIF) Liabilities and Shareholders Equity (2019 - 2026) Analysis & Trends
Green Thumb Industries' Liabilities and Shareholders Equity history runs 8 years deep, the most recent figure standing at $2.8 billion for Q1 2026.
- Quarterly Liabilities and Shareholders Equity rose 10.22% year-over-year to $2.8 billion in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $10.8 billion (up 6.37% YoY) and the FY2025 annual result came in at $2.8 billion, up 9.97% from the prior year.
- Liabilities and Shareholders Equity was $2.8 billion for Q1 2026 at Green Thumb Industries, up from $2.8 billion in the prior quarter.
- Across five years, Liabilities and Shareholders Equity topped out at $2.8 billion in Q1 2026 and bottomed at $2.4 billion in Q1 2022.
- A 5-year average of $2.5 billion and a median of $2.5 billion in 2024 frame the typical range for Liabilities and Shareholders Equity.
- Annual changes were most pronounced in 2022 — Liabilities and Shareholders Equity surged 54.74% — and 2025, when it advanced 0.3%.
- Green Thumb Industries' Liabilities and Shareholders Equity stood at $2.4 billion in 2022, then gained by 2.32% to $2.5 billion in 2023, then gained by 1.89% to $2.5 billion in 2024, then rose by 9.97% to $2.8 billion in 2025, then grew by 1.49% to $2.8 billion in 2026.
- Business Quant data shows GTBIF's Liabilities and Shareholders Equity at $2.8 billion in Q1 2026, $2.8 billion in Q4 2025, and $2.6 billion in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Liabilities and Shareholders Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - | 43.40 Bn |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn | 40.04 Bn |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn | 15.15 Bn |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn | 98.91 Bn |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn | 6.71 Bn |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - | 69.30 Bn |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn | 36.83 Bn |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn | 4.91 Bn |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn | 13.22 Bn |
| 10 | Green Thumb Industries | 1.63 Bn | 1.29 Bn | 143.65 Mn | 2.83 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 2.83 Bn |
| Dec 31, 2025 | 2.79 Bn |
| Sep 30, 2025 | 2.64 Bn |
| Jun 30, 2025 | 2.55 Bn |
| Mar 31, 2025 | 2.57 Bn |
| Dec 31, 2024 | 2.54 Bn |
| Sep 30, 2024 | 2.51 Bn |
| Jun 30, 2024 | 2.54 Bn |
| Mar 31, 2024 | 2.55 Bn |
| Dec 31, 2023 | 2.49 Bn |
| Sep 30, 2023 | 2.50 Bn |
| Jun 30, 2023 | 2.51 Bn |
| Mar 31, 2023 | 2.49 Bn |
| Dec 31, 2022 | 2.43 Bn |
| Sep 30, 2022 | 2.46 Bn |
| Jun 30, 2022 | 2.44 Bn |
| Mar 31, 2022 | 2.40 Bn |
| Dec 31, 2021 | 2.39 Bn |
| Sep 30, 2021 | 2.15 Bn |
| Jun 30, 2021 | 1.79 Bn |